ArticleAbdominal radiology (New York)2026
Segmental fECV measurement using PCD-CT as an early predictor of liver function decline in chronic liver disease.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to investigate the utility of segmental hepatic extracellular volume fractions (fECV) calculated using a photon-counting detector CT (PCD-CT) for predicting liver function decline, as reflected by the modified albumin-bilirubin (mALBI) grade in chronic liver disease (CLD). MATERIALS AND
methodsA total of 146 patients with CLD underwent PCD-CT of the liver, including 3-minute equilibrium phase imaging. Iodine densities of the aorta and liver segments (S2-S8), based on Couinaud's classification, were measured to calculate fECV. The diagnostic accuracy of segmental fECV for predicting early liver function decline was assessed using mALBI grade as the functional reference standard, with receiver operating characteristic (ROC) analysis.
resultsFor mALBI grades 1, 2b, and 3, no significant differences in fECV were found among segments. For mALBI grade 2a, fECV values were significantly larger in S4 and S5 compared to S2, S3, S6, and S7 (p < 0.05), and the fECV in S8 was significantly larger than in S7 (p < 0.05). The fECV values in S6 and S7 significantly increased with higher mALBI grade, while other segments showed less pronounced increases. ROC analysis revealed that fECV in S4, S5, and S8 demonstrated sensitivities, specificities, and accuracies of approximately 90% for predicting early liver function decline (distinguishing mALBI grade 1 from grades 2a or above).
conclusionSegmental fECV measurement using PCD-CT offers preliminary insights into liver function. Increased fECV in the medial (S4) and anterior (S5, S8) segments showed potential as an early indicator of functional decline, while fECV in the posterior segments (S6, S7) suggested utility in disease staging. As a proof-of-concept study, these findings require further validation before this approach can be adopted in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.